Crossmark

Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition

Crossref DOI link: https://doi.org/10.1007/s00259-023-06211-6

Published Online: 2023-04-22

Published Print: 2023-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zboralski, Dirk https://orcid.org/0000-0002-2224-2452
Osterkamp, Frank

Christensen, Esben

Bredenbeck, Anne

Schumann, Anne

Hoehne, Aileen

Schneider, Eberhard

Paschke, Matthias

Ungewiss, Jan

Haase, Christian

Robillard, Liliane

Simmons, Andrew D.

Harding, Thomas C.

Nguyen, Minh
License Information

Text and Data Mining valid from 2023-04-22

Version of Record valid from 2023-04-22
More Information

Article History

Received: 31 January 2023

Accepted: 18 March 2023

First Online: 22 April 2023

Declarations

:

: All animal experiments were carried out under licenses approved by the respective authorities and in compliance with guidelines on animal welfare.

: D. Zboralski, F. Osterkamp, A. Bredenbeck, A. Schumann, A. Hoehne, E. Schneider, M. Paschke, J. Ungewiss, C. Haase are employees of 3B Pharmaceuticals GmbH and are named inventors of FAP-2287. M. Paschke, and F. Osterkamp are cofounders of 3B Pharmaceuticals GmbH. E. Christensen is an employee of Minerva Imaging ApS. L. Robillard, A.D. Simmons, T.C. Harding and M. Nguyen are employees of Clovis Oncology, Inc., and may own stock or have stock options in the company.

Document is current

Any future updates will be listed below